^
Association details:
| Biomarker: | MGMT unmethylation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preliminary results of the abemaciclib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II platform trial using Bayesian adaptive randomization.
Published date:
05/19/2021
Excerpt:
Patients with newly diagnosed MGMT-unmethylated glioblastoma were randomized to receive...standard radiochemotherapy followed by adjuvant abemaciclib (150-200 mg orally BID)....PFS was significantly longer (HR 0.67; p = 0.03, logrank test) with abemaciclib (median 6.54 months) compared to the control arm (median 5.88 months). For patients with activation of the CDK4 pathway the PFS HR was 0.64 (p-value = 0.04).
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.2021.39.15_suppl.2014
